Diabetes is the #1 health challenge of the 21st century. Continuous Glucose Monitoring or CGM ($1.25B market in 2016, growing 29%/yr) is today’s cornerstone of “diabetes self-management” and the most effective solution to reduce the economic and societal burden of diabetes. But the shortcomings of current CGMs hinder their wider adoption: high cost, unsatisfactory predictability of severe events, and poor user comfort. The DiaMOND project removes these barriers by bringing a longterm, implantable, cost-effective Continuous Diabetes Monitoring (CDM®) to the market. The CDM sensor will, as a first, allow personalised management by accurately monitoring all the biomarkers at play in diabetes control, and not only glucose. CDM can prevent severe clinical events such as hypo- and hyperglycaemia and ketoacidosis, rather than just monitoring them. Indigo’s CDM uses Indigo's patented multi-biomarker spectrometer integrated on a chip that is implanted subcutaneously.
With DiaMOND Indigo has proven that it can measure glucose, ketones and lactate accurately, continuously and in RT in vivo in an animal model with its invisible, subcutaneously inserted sensor. Lactate has been identified as a potential marker for increased insulin need. A small-scale investigational clinical study is on its way to reproduce this demonstration. The market access strategy has been investigated including KOL involvement and dissemination to the broad public and diabetes community.
DiaMOND was of uttermost importance and detrimental to bring Indigo to the stage it is now, and the results will realm in the near future and strengthen Indigo’s path towards valorisation. This world’s first holds the promise to address the need of millions of people living with diabetes.
